{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:50:12Z","timestamp":1792101012590,"version":"4.4.0"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000921","name":"COST","doi-asserted-by":"crossref","award":["BM1101"],"award-info":[{"award-number":["BM1101"]}],"id":[{"id":"10.13039\/501100000921","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicon"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.toxicon.2015.09.010","type":"journal-article","created":{"date-parts":[[2015,9,12]],"date-time":"2015-09-12T11:39:57Z","timestamp":1442057997000},"page":"89-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"PA","title":["Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4552-4970","authenticated-orcid":false,"given":"Francesca","family":"Del Sorbo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5864-0006","authenticated-orcid":false,"given":"Alberto","family":"Albanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxicon.2015.09.010_bib1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1015291021312","article-title":"Assessing health status and quality-of-life instruments: attributes and review criteria","volume":"11","author":"Aaronson","year":"2002","journal-title":"Qual. Life Res."},{"key":"10.1016\/j.toxicon.2015.09.010_bib2","first-page":"345","article-title":"Comparison of botulinum toxin injection procedures in adductor spasmodic dysphonia","volume":"24","author":"Adams","year":"1995","journal-title":"J.\u00a0Otolaryngol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib3","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/mds.20098","article-title":"Safety and efficacy of botulinum toxin type B (Myobloc) in adductor spasmodic dysphonia","volume":"19","author":"Adler","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib4","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S1474-4422(14)70178-4","article-title":"Deep brain stimulation for cervical dystonia","volume":"13","author":"Albanese","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1468-1331.2010.03042.x","article-title":"EFNS guidelines on diagnosis and treatment of primary dystonias","volume":"18","author":"Albanese","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/mds.25579","article-title":"Dystonia rating scales: critique and recommendations","volume":"28","author":"Albanese","year":"2013","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib7","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/mds.26384","article-title":"Therapeutic advances in dystonia","volume":"30","author":"Albanese","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib8","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0363-5023(97)80155-4","article-title":"Assessment of the carpal tunnel outcome instrument in patients with nerve-compression symptoms","volume":"22","author":"Atroshi","year":"1997","journal-title":"J.\u00a0Hand Surg. Am."},{"key":"10.1016\/j.toxicon.2015.09.010_bib9","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A\u00a0new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib10","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/000348940010900215","article-title":"Effects of botulinum toxin on pathophysiology in spasmodic dysphonia","volume":"109","author":"Bielamowicz","year":"2000","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib11","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1177\/000348940111000503","article-title":"Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia","volume":"110","author":"Bielamowicz","year":"2001","journal-title":"Ann. Otol. Rhinol. Laryngol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/IOP.0b013e31819946c4","article-title":"High versus low concentration botulinum toxin A for benign essential blepharospasm: does dilution make a difference?","volume":"25","author":"Boyle","year":"2009","journal-title":"Ophthal. Plast. Reconstr. Surg."},{"key":"10.1016\/j.toxicon.2015.09.010_bib13","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","article-title":"Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial","volume":"46","author":"Brans","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib14","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1212\/WNL.53.7.1439","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia","volume":"53","author":"Brashear","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib15","series-title":"Treatment of Movement Disorders","first-page":"183","article-title":"Treatment of dystonia using botulinum toxin","author":"Brin","year":"1995"},{"key":"10.1016\/j.toxicon.2015.09.010_bib16","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1212\/WNL.53.7.1431","article-title":"Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia","volume":"53","author":"Brin","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib17","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1212\/WNL.35.1.73","article-title":"Validity and reliability of a rating scale for the primary torsion dystonias","volume":"35","author":"Burke","year":"1985","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib18","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1212\/01.WNL.0000142962.11881.26","article-title":"Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58)","volume":"63","author":"Cano","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/1531-8257(199903)14:2<307::AID-MDS1016>3.0.CO;2-3","article-title":"Effect of muscle activity immediately after botulinum toxin injection for writer's cramp","volume":"14","author":"Chen","year":"1999","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib20","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1002\/mds.870100411","article-title":"Double-blind trial of botulinum toxin for treatment of focal hand dystonia","volume":"10","author":"Cole","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib21","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","article-title":"Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia","volume":"65","author":"Comella","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J.\u00a0Neurol. Sci."},{"key":"10.1016\/j.toxicon.2015.09.010_bib23","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/mds.10377","article-title":"Rating scales for dystonia: a multicenter assessment","volume":"18","author":"Comella","year":"2003","journal-title":"Mov. Disord."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.toxicon.2015.09.010_bib24","first-page":"445","article-title":"The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability","volume":"40","author":"Consky","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib25","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clinph.2007.07.004","article-title":"Sensory integration in writer's cramp: comparison with controls and evaluation of botulinum toxin effect","volume":"118","author":"Contarino","year":"2007","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/0277-9536(92)90240-Q","article-title":"Sickness impact profile: the state of the art of a generic functional status measure","volume":"35","author":"de Bruin","year":"1992","journal-title":"Soc. Sci. Med."},{"issue":"Suppl.\u00a0l","key":"10.1016\/j.toxicon.2015.09.010_bib27","doi-asserted-by":"crossref","first-page":"142S","DOI":"10.1016\/S0197-2456(05)80019-4","article-title":"Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation","volume":"12","author":"Deyo","year":"1991","journal-title":"Control Clin. Trials"},{"key":"10.1016\/j.toxicon.2015.09.010_bib28","series-title":"The Quantification of Neurological Deficit","first-page":"241","article-title":"Assessment of the primary dystonias","author":"Fahn","year":"1989"},{"key":"10.1016\/j.toxicon.2015.09.010_bib29","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1097\/00005537-199908000-00021","article-title":"Increased stability of airflow following botulinum toxin injection","volume":"109","author":"Finnegan","year":"1999","journal-title":"Laryngoscope"},{"key":"10.1016\/j.toxicon.2015.09.010_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta2140","article-title":"Evaluating patient-based outcome measures for use in clinical trials","volume":"2","author":"Fitzpatrick","year":"1998","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.toxicon.2015.09.010_bib31","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1017\/S0317167100038506","article-title":"Localizing muscles for botulinum toxin treatment of focal hand dystonia","volume":"23","author":"Geenen","year":"1996","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.toxicon.2015.09.010_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/mds.870110107","article-title":"Unilateral injection of botulinum toxin in blepharospasm: single fiber electromyography and blink reflex study","volume":"11","author":"Girlanda","year":"1996","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1212\/01.wnl.0000342200.58823.6a","article-title":"Levels of evidence: taking neurology to the next level","volume":"72","author":"Gross","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"10.1016\/j.toxicon.2015.09.010_bib35","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib36","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.22368","article-title":"Relationship between various clinical outcome assessments in patients with blepharospasm","volume":"24","author":"Jankovic","year":"2009","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib38","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/bmj.307.6901.449","article-title":"The SF 36 health survey questionnaire....if used within its limits","volume":"307","author":"Jenkinson","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.toxicon.2015.09.010_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ncl.2014.09.002","article-title":"Diagnosis and treatment of dystonia","volume":"33","author":"Jinnah","year":"2015","journal-title":"Neurol. Clin."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.toxicon.2015.09.010_bib40","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.parkreldis.2011.06.018","article-title":"Debunking the pathophysiological puzzle of dystonia\u2013with special reference to botulinum toxin therapy","volume":"17","author":"Kanovsky","year":"2011","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib41","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/jnnp.2005.083170","article-title":"Botulinum toxin for writer's cramp: a randomised, placebo-controlled trial and 1-year follow-up","volume":"78","author":"Kruisdijk","year":"2007","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.09.010_bib42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/PHM.0b013e3181bc0c78","article-title":"Effect of botulinum toxin injection on nocturnal bruxism: a randomized controlled trial","volume":"89","author":"Lee","year":"2010","journal-title":"Am. J. Phys. Med. Rehabil."},{"key":"10.1016\/j.toxicon.2015.09.010_bib43","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1212\/WNL.49.3.701","article-title":"Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystonia","volume":"49","author":"Lew","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib44","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/mds.870100407","article-title":"The blepharospasm disability scale: an instrument for the assessment of functional health in blepharospasm","volume":"10","author":"Lindeboom","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib45","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1212\/WNL.38.8.1220","article-title":"Effects of botulinum toxin injections on speech in adductor spasmodic dysphonia","volume":"38","author":"Ludlow","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib46","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1749-4486.2010.02194.x","article-title":"Oromandibular dystonia questionnaire (OMDQ-25): a valid and reliable instrument for measuring health-related quality of life","volume":"35","author":"Merz","year":"2010","journal-title":"Clin. Otolaryngol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib47","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1037\/0003-066X.50.9.741","article-title":"Validation of inferences from persons' responses and performances as scientific enquiry into score meaning","volume":"50","author":"Messick","year":"1995","journal-title":"Am. Psychol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib48","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.toxicon.2015.09.010_bib49","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1212\/WNL.58.5.805","article-title":"Accuracy of muscle localization without EMG: implications for treatment of limb dystonia","volume":"58","author":"Molloy","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib50","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A\u00a0new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.09.010_bib51","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/jnnp.2003.013441","article-title":"Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument","volume":"75","author":"Muller","year":"2004","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.09.010_bib52","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00941758","article-title":"Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm","volume":"235","author":"Nussgens","year":"1997","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib53","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.parkreldis.2007.03.006","article-title":"Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm","volume":"13","author":"Ochudlo","year":"2007","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib54","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/jnnp.64.1.6","article-title":"A\u00a0double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia","volume":"64","author":"Odergren","year":"1998","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.09.010_bib55","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mds.21724","article-title":"Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial","volume":"23","author":"Pappert","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib56","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group","volume":"64","author":"Poewe","year":"1998","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.09.010_bib57","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenkamper","year":"2006","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.toxicon.2015.09.010_bib58","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/mds.870120627","article-title":"DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A\u2013Dysport and Botox\u2013assuming a ratio of 4:1","volume":"12","author":"Sampaio","year":"1997","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib59","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1097\/00005650-198807000-00007","article-title":"The MOS short-form general health survey. Reliability and validity in a patient population","volume":"26","author":"Stewart","year":"1988","journal-title":"Med. Care"},{"key":"10.1016\/j.toxicon.2015.09.010_bib60","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1288\/00005537-199106000-00010","article-title":"Double-blind controlled study of botulinum toxin in adductor spasmodic dysphonia","volume":"101","author":"Troung","year":"1991","journal-title":"Laryngoscope"},{"key":"10.1016\/j.toxicon.2015.09.010_bib61","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","article-title":"Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia","volume":"16","author":"Truong","year":"2010","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib62","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.parkreldis.2007.11.003","article-title":"Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial","volume":"14","author":"Truong","year":"2008","journal-title":"Parkinsonism. Relat. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib63","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/mds.20403","article-title":"Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study","volume":"20","author":"Truong","year":"2005","journal-title":"Mov. Disord."},{"key":"10.1016\/j.toxicon.2015.09.010_bib64","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1212\/WNL.43.1_Part_1.183","article-title":"Botulinum toxin in the treatment of writer's cramp: a double-blind study","volume":"43","author":"Tsui","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.toxicon.2015.09.010_bib65","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis","volume":"2","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.toxicon.2015.09.010_bib66","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(14)70143-7","article-title":"Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial","volume":"13","author":"Volkmann","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib67","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00702-010-0529-x","article-title":"Double-blind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm","volume":"118","author":"Wabbels","year":"2011","journal-title":"J.\u00a0Neural Transm."},{"issue":"8","key":"10.1016\/j.toxicon.2015.09.010_bib68","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1097\/00005537-200008000-00028","article-title":"Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a crossover design study of unilateral versus bilateral injection","volume":"110","author":"Warrick","year":"2000","journal-title":"Laryngoscope"},{"key":"10.1016\/j.toxicon.2015.09.010_bib69","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/jnnp.61.2.172","article-title":"Botulinum toxin in writer's cramp: objective response evaluation in 31 patients","volume":"61","author":"Wissel","year":"1996","journal-title":"J.\u00a0Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.toxicon.2015.09.010_bib70","first-page":"209","article-title":"Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia","volume":"24","author":"Wong","year":"1995","journal-title":"J.\u00a0Otolaryngol."},{"key":"10.1016\/j.toxicon.2015.09.010_bib71","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1212\/WNL.42.3.627","article-title":"Botulinum toxin therapy for limb dystonias","volume":"42","author":"Yoshimura","year":"1992","journal-title":"Neurology"}],"container-title":["Toxicon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010115300696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041010115300696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T02:52:47Z","timestamp":1718074367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041010115300696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":71,"alternative-id":["S0041010115300696"],"URL":"https:\/\/doi.org\/10.1016\/j.toxicon.2015.09.010","relation":{},"ISSN":["0041-0101"],"issn-type":[{"value":"0041-0101","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials","name":"articletitle","label":"Article Title"},{"value":"Toxicon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxicon.2015.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}